ClinicalTrials.gg
CompletedNCT00394121Updated Aug 27, 2010

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

A Phase 3 interventional study of Fluticasone propionate/formoterol fumarate in Asthma, sponsored by SkyePharma AG. Completed at 28 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2010-08-27.

Sponsored by SkyePharma AG · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Planned enrollment
43rd of 146
400 · median 100
Started
2006
with 5 others
Phase 3
35 of 147
none open now
Registered
23rd of 147
by date

Among the 147 studies testing fluticasone in Asthma, this one is the 43rd largest by planned enrollment of the 146 interventional ones that give a count, is one of 6 that started in 2006, is one of 35 in phase 3, and was the 23rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety of the fixed combination asthma drug FlutiForm HFA MDI (containing fluticasone propionate and formoterol fumarate) in adult and adolescent patients with mild to moderate-severe asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Fluticasone Propionate
  • Formoterol Fumarate
  • Pressurized metered does inhaler
  • Hydrofluoroalkane
  • Mild to moderate-severe asthma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Ages eligible for study: 12 years and above; genders eligible for study: both; prior use: steroid-requiring.

Inclusion criteria

Inclusion Criteria:

  • History of asthma for at least 12 months.
  • Documented use of inhaled corticosteriod for at least 4 weeks prior to Screening Visit Demonstrate FEV-1 of 40-80% of predicted normal values at Screening and Baseline Visit.
  • Documented reversibility of 15% within 6 months of Screening Visit or at Screening Visit (15% increase from pre-FEV-1 levels following albuterol inhalation).
  • Symptoms of Asthma during Run-in.
  • Females of must have a negative urine pregnancy test at Screening and Baseline Visits. Females are eligible only if they are not pregnant or lactating and are either sterile or using acceptable methods of .
  • Must otherwise be healthy.
  • Provide written . Wishes of minors must be respected.

Exclusion criteria

Exclusion Criteria:

  • Life-threatening asthma within past year or during Run-in Period.
  • History of systemic medication within 3 months before Screening Visit.
  • History of omalizumab use within the past 6 months.
  • History of leukotriene receptor antagonist use, e.g., montelukast, within the past week.
  • Current evidence of history of any disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia.
  • Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during Run-in Period.
  • Significant, non-reversible, pulmonary disease (e.g., [COPD], cystic fibrosis, bronchiectasis).
  • Known (HIV)-positive status.
  • Smoking history equivalent to "10 pack years".
  • Current smoking history within 12 months prior to Screening Visit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Long-term safety after twice daily treatment with FlutiForm HFA MDI over 12 months.

Secondary outcomes

  1. Long-term efficacy after twice daily treatment with FlutiForm HFA MDI over 12 months.

07

Study locations

28 sites
  • Research Site
    Berlin, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Mainz, Germany
  • Research Site
    Rudersdorf, Germany
  • Research Site
    Solingen, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Deszk, Hungary
  • Research Site
    Kecskemet, Hungary
  • Research Site
    Miskolc, Hungary
  • Research Site
    Mosonmagyarovar, Hungary
  • Research Site
    Bialystok, Poland
  • Research Site
    Gdansk, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Lodz, Poland
  • Research Site
    Wroclaw, Poland
  • Research Site
    Bucharest, Romania
  • Research Site
    Birmingham, United Kingdom
  • Research Site
    Carrickfergus, United Kingdom
  • Research Site
    Chippenham, United Kingdom
  • Research Site
    Cottingham, United Kingdom
  • Research Site
    Coventry, United Kingdom
  • Research Site
    Downpatrick, United Kingdom
  • Research Site
    Heywood, United Kingdom
  • Research Site
    Manchester, United Kingdom
  • Research Site
    Sheffield, United Kingdom
  • Research Site
    Solihull, United Kingdom
  • Research Site
    Sunbury on Thames, United Kingdom
  • Research Site
    Swindon Wilts, United Kingdom
08

References and documents

Publications

  • Mansur AH, Kaiser K. Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma. J Aerosol Med Pulm Drug Deliv. 2013 Aug;26(4):190-9. doi: 10.1089/jamp.2012.0977. Epub 2012 Oct 25. PubMed 23098325 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2006
First posted
Oct 31, 2006
Start
Mar 2006
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Results delay requested
Aug 24, 2010
Last update
Aug 27, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00394121
Lead sponsor
SkyePharma AG
First posted
Oct 31, 2006
Start date
Mar 2006
Primary completion
Jul 2007
Completion
Jul 2007
Last update
Aug 27, 2010
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Formoterol

Start the discussion